# Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

> **NCT01885208** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 813 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** semaglutide
- **DRUG:** exenatide

## Key facts

- **NCT ID:** NCT01885208
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-02
- **Primary completion:** 2015-07-13
- **Final completion:** 2015-07-13
- **Target enrollment:** 813 (ACTUAL)
- **Last updated:** 2019-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01885208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01885208, "Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01885208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*